Highlights
– In the phase 3 MAGNITUDE trial, addition of niraparib to abiraterone acetate plus prednisone (AAP) improved radiographic progression‑free survival (previously reported) and produced clinically meaningful improvements in time to symptomatic progression and time to cytotoxic chemotherapy in patients with HRR‑altered metastatic castration‑resistant prostate cancer (mCRPC), particularly those with BRCA1/2 alterations.
– At a median follow‑up of 37.3 months, final overall survival (OS) analysis showed no statistically significant OS advantage for niraparib + AAP versus placebo + AAP in the prespecified HRR‑altered population (HR 0.931; 95% CI 0.720–1.203; p=0.585) or BRCA1/2 subgroup (HR 0.788; 95% CI 0.554–1.120; nominal p=0.183).